The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J., Grant, B., Jones, J. A., Wierda, W. G., Zhao, W., Heerema, N. A., Johnson, A. J., Anh Tran, A., Clow, F., Kunkel, L., James, D. F., O'Brien, S. AMER SOC HEMATOLOGY. 2012

View details for Web of Science ID 000313838900268